Page 3 - Small Pharma News Today

With MDMA on track to gain United States Food and Drug Administration (FDA) approval for the treatment of post-traumatic stress disorder (PTSD) in 2024, Big...

• Results suggest that SSRIs enhance the efficacy of SPL026 when administered to MDD patients on a stable dose of SSRIs versus patients not on SSRIs • At Week 4, 100% of patients in the SSRI...

• Results suggest that SSRIs enhance the efficacy of SPL026 (DMT) when administered to MDD patients on a stable dose of SSRIs versus patients not on SSRIs

• Results suggest that SSRIs enhance the efficacy of SPL026 (DMT) when administered to MDD patients on a stable dose of SSRIs versus patients not on SSRIs ...

Filament Health Corp (OTCQB:FLHLF)s diversified business model makes it one of the only psychedelics companies to be already generating revenue.   The...

The psychedelic drug market is on the brink of extraordinary growth, projected to soar to $7.2 billion by 2029, reflecting a robust 55 per cent compound annual growth rate (CAGR), according to a report on Monday.This ascent is propelled by ...

Clinical-stage psychedelics biotech Cybin (NYSE: CYBN) has completed enrollment in its Phase 2 study of novel deuterated psilocybin analog CYB003 for the potential treatment of Major Depressive Disorder (MDD.) 

Cybin Inc. (NYSE-A:CYBN, NEO:CYBN) shares maintained upward momentum on Wednesday after soaring earlier this week on the news New York Mets owner Steve...

Billionaire hedge fund and NY Mets owner, Steve Cohen amped up his support for psychedelics R&D through a new investment of nearly $19 million in beneficially owned shares of Cybin Inc. (NYSE: CYBN).

Visiongain has published a new report entitled Contract Research Organisations (CROs) Market Report 2023-2033: Forecasts by Service (Preclinical, Clinical, Laboratory Services, Consulting Services, Data Management